mercaptoethanol has been researched along with Neoplasms in 28 studies
Mercaptoethanol: A water-soluble thiol derived from hydrogen sulfide and ethanol. It is used as a reducing agent for disulfide bonds and to protect sulfhydryl groups from oxidation.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna." | 7.67 | The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987) |
| "We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna." | 3.67 | The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987) |
| "A randomized study in 20 patients with cancer was carried out to test the clinical efficacy of sodium-2-mercaptoethane sulfonate (ASTA D-7093; mesnum) as an agent to prevent urotoxic side effects (in particular, hemorrhagic cystitis) during cytostatic therapy with the oxazaphosphorines cyclophosphamide and ifosfamide." | 2.65 | Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. ( Brock, N; Burkert, H; Günther, U; Hoefer-Janker, H; Klein, HO; Mitrenga, D; Scheef, W; Schnitker, J; Voigtmann, R, 1979) |
| "Mesna may produce gastrointestinal and allergic reactions." | 2.38 | Ifosfamide and mesna. ( Dana, WJ; Schoenike, SE, 1990) |
| "Blocking ROS generation could prevent cancer initiation, whereas blockage of autophagy seems to be required for initiation of cancer." | 1.36 | A matter of balance between life and death: targeting reactive oxygen species (ROS)-induced autophagy for cancer therapy. ( Gibson, SB, 2010) |
| "Ifosfamide has broad cytotoxicity against solid tumors and may prove to be an important addition to high-dose combination chemotherapy regimens." | 1.28 | High-dose ifosfamide with mesna uroprotection: a phase I study. ( Antman, KH; Begg, CB; Eder, JP; Elias, AD; Frei, E; Shea, T, 1990) |
| "One hundred and forty-six patients with advanced malignant disease were treated with 6 different dosage schedules of ifosfamide (IFX)." | 1.28 | Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector. ( Falkson, CI; Falkson, G; Falkson, HC, 1989) |
| "The antitumor activity of ifosfamide in testicular cancer was not reduced by mesna." | 1.27 | Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients. ( Bremer, K; Niederle, N; Scheulen, ME; Schütte, J; Seeber, S, 1983) |
| "Patients with solid tumors showed the largest and patients with hematologic malignancies the smallest percentage increase in CK-BB after reactivation." | 1.27 | Reactivation of serum creatine kinase isoenzyme BB in patients with malignancies. ( Abbott, LB; Lott, JA, 1984) |
| "Thirty-two patients with advanced cancer were treated in a phase I-II trial with ifosfamide plus mesnum." | 1.26 | Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment. ( Falkson, G; Falkson, HC; Stapelberg, R; Van Dyk, JJ, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (82.14) | 18.7374 |
| 1990's | 3 (10.71) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (3.57) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Click, RE | 1 |
| Gibson, SB | 1 |
| RO, TS | 1 |
| BUSCH, H | 1 |
| EDWARDS, CL | 1 |
| GENGOZIAN, N | 1 |
| de Kraker, J | 1 |
| Voûte, PA | 1 |
| Klein, HO | 2 |
| Wickramanayake, PD | 1 |
| Coerper, C | 1 |
| Christian, E | 1 |
| Pohl, J | 1 |
| Brock, N | 3 |
| Burkert, H | 2 |
| Scheulen, ME | 1 |
| Niederle, N | 1 |
| Bremer, K | 1 |
| Schütte, J | 1 |
| Seeber, S | 1 |
| Abbott, LB | 1 |
| Lott, JA | 1 |
| Czownicki, Z | 1 |
| Utracka-Hutka, B | 1 |
| Falkson, G | 2 |
| Van Dyk, JJ | 1 |
| Stapelberg, R | 1 |
| Falkson, HC | 2 |
| Lee, IS | 1 |
| Shamon, LA | 1 |
| Chai, HB | 1 |
| Chagwedera, TE | 1 |
| Besterman, JM | 1 |
| Farnsworth, NR | 1 |
| Cordell, GA | 1 |
| Pezzuto, JM | 1 |
| Kinghorn, AD | 1 |
| Matre, R | 1 |
| Tönder, O | 1 |
| Thunold, S | 1 |
| Solhaug, JH | 1 |
| Scheef, W | 1 |
| Günther, U | 1 |
| Hoefer-Janker, H | 1 |
| Mitrenga, D | 1 |
| Schnitker, J | 1 |
| Voigtmann, R | 1 |
| Elias, AD | 1 |
| Eder, JP | 1 |
| Shea, T | 1 |
| Begg, CB | 1 |
| Frei, E | 1 |
| Antman, KH | 1 |
| Schoenike, SE | 1 |
| Dana, WJ | 1 |
| Pratt, CB | 2 |
| Douglass, EC | 1 |
| Etcubanas, E | 1 |
| Goren, MP | 2 |
| Green, AA | 1 |
| Hayes, FA | 1 |
| Horowitz, ME | 1 |
| Meyer, WH | 2 |
| Thompson, EI | 1 |
| Wilimas, JA | 1 |
| Falkson, CI | 1 |
| Wright, RK | 1 |
| Dodge, RK | 1 |
| Viar, MJ | 1 |
| Andriole, GL | 1 |
| Sandlund, JT | 1 |
| Miser, JS | 1 |
| Arasi, V | 1 |
| Linehan, M | 1 |
| Magrath, IT | 1 |
| Shaw, IC | 1 |
| Graham, MI | 1 |
| Li, GC | 1 |
| Li, JQ | 1 |
| Guan, ZZ | 1 |
| He, YJ | 1 |
| Deem, RL | 1 |
| Targan, SR | 1 |
| Lille-Szyszkowicz, I | 1 |
| Gabay, P | 1 |
| Podliachouk, L | 1 |
| Eyquem, A | 1 |
| Bourdin, JS | 1 |
| Saracino, RT | 1 |
| Olsen, RG | 1 |
| Yohn, DS | 1 |
| Wu, JT | 1 |
| Madsen, A | 1 |
| Bray, PF | 1 |
3 reviews available for mercaptoethanol and Neoplasms
| Article | Year |
|---|---|
Potential alteration of tumor microenvironments by β-mercaptoethanol.
Topics: Antigens, Neoplasm; Cell Differentiation; Cell Proliferation; Humans; Immune Checkpoint Inhibitors; | 2021 |
Ifosfamide and mesna.
Topics: Animals; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1990 |
Mesna--a short review.
Topics: Cystitis; Expectorants; Humans; Mercaptoethanol; Mesna; Neoplasms | 1987 |
3 trials available for mercaptoethanol and Neoplasms
| Article | Year |
|---|---|
Clinical overview of mesna.
Topics: Clinical Trials as Topic; Cyclophosphamide; Drug Interactions; Hematuria; Humans; Ifosfamide; Mercap | 1983 |
[Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
Topics: Clinical Trials as Topic; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Mercaptoethanol | 1981 |
Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.
Topics: Clinical Trials as Topic; Cystitis; Drug Therapy, Combination; Hematuria; Humans; Male; Mercaptoetha | 1979 |
22 other studies available for mercaptoethanol and Neoplasms
| Article | Year |
|---|---|
A matter of balance between life and death: targeting reactive oxygen species (ROS)-induced autophagy for cancer therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Humans; Mercaptoet | 2010 |
IN VITRO LABELING OF RNA IN ISOLATED NUCLEOLI OF THE WALKER TUMOR AND LIVER.
Topics: Animals; Carcinoma 256, Walker; Cell Nucleolus; Cell Nucleus; Dactinomycin; Enzyme Inhibitors; Histo | 1964 |
AUTO-IMMUNE HEMOLYTIC ANEMIA TREATED WITH D-PENICILLAMINE; REPORT OF A CASE.
Topics: Anemia; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Autoantibodies; Blood Transfusion; Drug Th | 1965 |
Proceedings of a symposium on ifosfamide (Mitoxana; Holoxan) and Mesna (Uromitexan). Coventry, U.K., 16-18 March 1983.
Topics: Animals; Cyclophosphamide; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1983 |
Ifosfamide, mesna and vincristine in paediatric oncology.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Ifosfam | 1983 |
High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.
Topics: Cyclophosphamide; Drug Evaluation; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1983 |
Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.
Topics: Cyclophosphamide; Drug Evaluation; Drug Interactions; Female; Humans; Ifosfamide; Male; Mercaptoetha | 1983 |
Reactivation of serum creatine kinase isoenzyme BB in patients with malignancies.
Topics: Adenylate Kinase; Alzheimer Disease; Blood Protein Electrophoresis; Chelating Agents; Creatine Kinas | 1984 |
Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Ifosfamide; Kidney Diseases; Leukopenia; Male; Mercap | 1982 |
Cell-cycle specific cytotoxicity mediated by rearranged ent-kaurene diterpenoids isolated from Parinari curatellifolia.
Topics: Africa; Cell Cycle; Cell Division; Cell Line; Cysteine; Diterpenes; Flow Cytometry; G2 Phase; Humans | 1996 |
Properties of Fcgamma receptors in normal and malignant human tissues.
Topics: Azides; Binding Sites, Antibody; Edetic Acid; Erythrocytes; Formaldehyde; Humans; Hydrogen-Ion Conce | 1976 |
High-dose ifosfamide with mesna uroprotection: a phase I study.
Topics: Blood; Bone Marrow; Central Nervous System; Dose-Response Relationship, Drug; Drug Evaluation; Drug | 1990 |
Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Humans; Ifosfamide; Infant; Mercaptoethanol; M | 1989 |
Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Mi | 1989 |
Mesna excretion and ifosfamide nephrotoxicity in children.
Topics: Adolescent; Adult; Child; Child, Preschool; Creatinine; Female; Humans; Ifosfamide; Kidney Diseases; | 1989 |
Recent experience with ifosfamide/mesna in solid tumors. International satellite symposium to the 3rd European Conference on Clinical Oncology. Stockholm, June 1985. Proceedings.
Topics: Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1986 |
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
Topics: Adolescent; Adult; Child; Child, Preschool; Cyclophosphamide; Cystitis; Female; Hematuria; Hemorrhag | 1987 |
Ifosfamide and Mesna in advanced malignancies.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Lymphom | 1988 |
Analysis of sequential substages of the natural killer cell lethal hit.
Topics: Antimetabolites; Cross-Linking Reagents; Cytotoxicity, Immunologic; Glutaral; Humans; In Vitro Techn | 1985 |
[Contribution to the study of anti-gamma globulins in the serum of cancer patients].
Topics: Adolescent; Adult; Antibodies; Antigens; Bronchial Neoplasms; Erythrocytes; gamma-Globulins; Gastroi | 1969 |
Immunodiffusion analysis of Yaba poxvirus structural and associated antigens.
Topics: Animals; Antigens; Cell Line; Centrifugation, Density Gradient; Cesium; Chlorides; Complement Fixati | 1970 |
Quantitative measurement and chromatography of human urinary carcinoembryonic antigen activity.
Topics: Adolescent; Adult; Carcinoembryonic Antigen; Child; Child, Preschool; Chromatography; Female; Guanid | 1974 |